Q3'25 Psychedelic Lobbying Update

Psychedelic Alpha provides a quarterly update on federal lobbying disclosures tied to psychedelic drug developers and nonprofits. The update highlights that federal lobbying spend among psychedelic drug developers reached a new high in Q3 2025, based on disclosures summarized via the site’s Psychedelics Federal Lobbying Tracker. The piece notes that quarterly filings lag real-world activity. It also flags how individual company actions can shift the totals, including Lykos Therapeutics terminating its federal lobbying spend after being identified as the biggest spender over the prior two years. Overall, the update frames lobbying data as an imperfect but useful lagging indicator for policy and regulatory momentum.